Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A systematic assessment of the epidemiologic literature regarding an association between acetaminophen exposure and cancer.
Weinstein R, Parikh-Das AM, Salonga R, Schuemie M, Ryan PB, Atillasoy E, Hermanowski-Vosatka A, Eichenbaum G, Berlin JA. Weinstein R, et al. Among authors: hermanowski vosatka a. Regul Toxicol Pharmacol. 2021 Dec;127:105043. doi: 10.1016/j.yrtph.2021.105043. Epub 2021 Sep 10. Regul Toxicol Pharmacol. 2021. PMID: 34517075 Free article.
A critical review of the acetaminophen preclinical carcinogenicity and tumor promotion data and their implications for its carcinogenic hazard potential.
Murray FJ, Monnot AD, Jacobson-Kram D, Cohen SM, Hardisty JF, Bandara SB, Kovochich M, Deore M, Pitchaiyan SK, Gelotte CK, Lai JCK, Atillasoy E, Hermanowski-Vosatka A, Kuffner E, Unice KM, Yang K, Gebremichael Y, Howell BA, Eichenbaum G. Murray FJ, et al. Among authors: hermanowski vosatka a. Regul Toxicol Pharmacol. 2020 Dec;118:104801. doi: 10.1016/j.yrtph.2020.104801. Epub 2020 Oct 9. Regul Toxicol Pharmacol. 2020. PMID: 33039518 Free article. Review.
Assessment of the biochemical pathways for acetaminophen toxicity: Implications for its carcinogenic hazard potential.
Jaeschke H, Murray FJ, Monnot AD, Jacobson-Kram D, Cohen SM, Hardisty JF, Atillasoy E, Hermanowski-Vosatka A, Kuffner E, Wikoff D, Chappell GA, Bandara SB, Deore M, Pitchaiyan SK, Eichenbaum G. Jaeschke H, et al. Among authors: hermanowski vosatka a. Regul Toxicol Pharmacol. 2021 Mar;120:104859. doi: 10.1016/j.yrtph.2020.104859. Epub 2021 Jan 1. Regul Toxicol Pharmacol. 2021. PMID: 33388367 Free article. Review.
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation.
Zhang L, Yan X, Fox KAA, Willmann S, Nandy P, Berkowitz SD, Hermanowski-Vosatka A, Weitz JI, Solms A, Schmidt S, Patel M, Peters G. Zhang L, et al. Among authors: hermanowski vosatka a. J Thromb Thrombolysis. 2020 Jul;50(1):20-29. doi: 10.1007/s11239-020-02077-9. J Thromb Thrombolysis. 2020. PMID: 32323192 Free PMC article. Clinical Trial.
Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome.
Zhang L, Yan X, Nandy P, Willmann S, Fox KAA, Berkowitz SD, Sharma A, Hermanowski-Vosatka A, Schmidt S, Weitz JI, Garmann D, Peters G. Zhang L, et al. Among authors: hermanowski vosatka a. Ther Adv Cardiovasc Dis. 2019 Jan-Dec;13:1753944719863641. doi: 10.1177/1753944719863641. Ther Adv Cardiovasc Dis. 2019. PMID: 31364490 Free PMC article.
Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling.
Solms A, Frede M, Berkowitz SD, Hermanowski-Vosatka A, Kubitza D, Mueck W, Spiro TE, Willmann S, Yan X, Zhang L, Garmann D. Solms A, et al. Among authors: hermanowski vosatka a. CPT Pharmacometrics Syst Pharmacol. 2019 Nov;8(11):805-814. doi: 10.1002/psp4.12444. Epub 2019 Jul 5. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 31276324 Free PMC article.
Pharmacokinetic-pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects.
Wright DH, Stone JA, Crumley TM, Wenning L, Zheng W, Yan K, Yang AY, Sun L, Cilissen C, Ramael S, Hermanowski-Vosatka A, Langdon RB, Gottesdiener KM, Wagner JA, Lai E. Wright DH, et al. Among authors: hermanowski vosatka a. Br J Clin Pharmacol. 2013 Dec;76(6):917-31. doi: 10.1111/bcp.12131. Br J Clin Pharmacol. 2013. PMID: 23594227 Free PMC article. Clinical Trial.
11β-HSD1 inhibition reduces atherosclerosis in mice by altering proinflammatory gene expression in the vasculature.
Luo MJ, Thieringer R, Springer MS, Wright SD, Hermanowski-Vosatka A, Plump A, Balkovec JM, Cheng K, Ding GJ, Kawka DW, Koo GC, Grand CB, Luo Q, Maletic MM, Malkowitz L, Shah K, Singer I, Waddell ST, Wu KK, Yuan J, Zhu J, Stepaniants S, Yang X, Lum PY, Wang IM. Luo MJ, et al. Among authors: hermanowski vosatka a. Physiol Genomics. 2013 Jan 7;45(1):47-57. doi: 10.1152/physiolgenomics.00109.2012. Epub 2012 Nov 20. Physiol Genomics. 2013. PMID: 23170035
40 results